Syndax Pharmaceuticals to Present at the SITC 31st Annual Scientific Meeting
November 08, 2016 09:26 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
Syndax to Announce Third Quarter 2016 Financial Results and Host Conference Call and Webcast on November 10, 2016
October 28, 2016 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its third quarter 2016 financial results on Thursday, November 10, 2016, after the...
Syndax Pharmaceuticals Announces Participation at Four Upcoming Investor Conferences
September 06, 2016 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in...
Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
August 09, 2016 06:30 ET
|
Syndax Pharmaceuticals, Inc.
Expanded pipeline with potentially best-in-class, IND-ready anti-CSF-1R antibodyProgressing to Phase 2 of ENCORE 601 in NSCLC and Melanoma Initiated ENCORE 602 for TNBC in collaboration with Genentech...
Syndax Appoints Leading Experts to Scientific Advisory Board (SAB)
July 27, 2016 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on the development of novel anti-cancer therapies,...
Syndax to Announce Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9, 2016
July 20, 2016 16:01 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its second quarter 2016 financial results on Tuesday, August 9, 2016, before the opening...
Syndax Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
July 07, 2016 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., July 07, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy...
Syndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB’s Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program
July 06, 2016 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer...
Syndax Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
June 14, 2016 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat broadly as a combination...
Entinostat Data to be Highlighted at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
May 18, 2016 17:20 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer...